All News

In vivo CAR T-cell engineering represents a fundamental rethinking of how cellular therapies are produced and delivered.

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

The safety profile of zocilurtatug pelitecan among patients with extrapulmonary neuroendocrine carcinomas was consistent with prior reports in SCLC.

Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.

New trials reshape gastroesophageal adenocarcinoma care with durvalumab‑FLOT, HER2, and CLDN18.2 targets, plus practical toxicity tips.

Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases like NSCLC and oral premalignant lesions.

Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

Patrick A. Kenney, MD, and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.

According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.

The FDA has set a new Prescription Drug User Fee Act date of July 23, 2026, for subcutaneous isatuximab plus standard of care in multiple myeloma.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

Preliminary data from the phase 1/1b RMC-9805-001 study support continued development of zoldonrasib as a therapeutic strategy in this population.

Data from a phase 1 trial suggest that durable, vaccine-induced T-cell memory may be achievable even in pancreatic ductal adenocarcinoma.

Diane Simeone, MD, discussed results from the RASolute 302 trial, which showed improved overall survival with daraxonrasib vs SOC in metastatic PDAC.

Findings from a phase 1 trial showed no adverse effects higher than grade 3 among those who received ruxolitinib/abemaciclib for advanced myelofibrosis.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

New findings presented at the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Early trials exploring the efficacy of PD-1 blockade in Hodgkin lymphoma inspired the SWOG S1826 trial, which evaluated the agent with AVD in this population.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

All patients who received cilta-cel in the phase 2 CAR-PRISM trial achieved MRD negativity per next-generation sequencing.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.